Your session is about to expire
← Back to Search
Pemigatinib for Bladder Cancer
Study Summary
This trial is testing a drug called Pemigatinib to see if it can treat patients with a history of low- or intermediate-risk non-muscle invasive bladder cancer who have recurrent tumors. If the drug is effective, it will be given to patients 4-6 weeks before they undergo a standard treatment called transurethral resection of bladder tumor.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 147 Patients • NCT02924376Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I received my last cancer treatment less than 4 weeks ago or am still experiencing side effects.Your test results must be within certain ranges.I haven't had major surgery or significant injury in the last 4 weeks, or minor procedures in the last week.I have been treated with specific drugs targeting fibroblast growth factor receptors.My bladder cancer is confirmed to be at a low or intermediate risk and has not invaded the muscle.I had radiotherapy less than 4 weeks ago or am still experiencing side effects.I have a non-invasive cancer in my kidney or ureter.I have another cancer besides non-melanoma skin cancer or prostate cancer that is not actively growing.I am 18 years old or older.My latest urine test shows high grade bladder cancer.I can take care of myself and perform daily activities.
- Group 1: Treatment: Pemigatinib
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other exploratory investigations have been conducted on Pemigatinib?
"Presently, 13 medical trials are exploring the use of pemigatinib; one is in phase 3. In addition to Aachen, California, 644 other sites offer clinical trials incorporating this medication."
How many participants are currently involved in this medical experiment?
"Affirmative. The details on clinicaltrials.gov clearly show that this research project, which was initially posted in October 2020 is currently recruiting individuals for the trial. 43 participants are needed from 1 site."
Is this the inaugural instance of this kind of medical research?
"Since the inaugural study sponsored by Incyte Corporation in 2017, which included 47 participants, Pemigatinib has been under intense investigation. After receiving positive results from its Phase 2 trial approval, there are now 13 active studies occuring at 98 cities and 41 countries worldwide."
Is it possible to still join this experiment?
"As per the details on clinicaltrials.gov, this research is actively recruiting patients since its initial posting date of October 2nd 2020 and most recently updated on October 31st 2022."
What maladies has Pemigatinib been demonstrated to improve?
"Patients with unresectable, metastatic cholangiocarcinomas can implement pemigatinib as part of their advance directive to target the fgfr2 protein in humans."
Has Pemigatinib been sanctioned by the FDA?
"Based on our analysis, Pemigatinib has been assigned a score of 2 which reflects the fact that there is limited data surrounding its efficacy and some clinical evidence for safety due to this being a phase 2 trial."
Share this study with friends
Copy Link
Messenger